Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors

Science Translational Medicine

Volumn 6, Issue 227, 2014, Pages

  Dobard, Charles ^a   Sharma, Sunita ^a   Parikh, Urvi M ^a   West, Rolieria ^a   Taylor, Andrew ^a   Martin, Amy ^a   Pau, Chou Pong ^a   Hanson, Debra L ^a   Lipscomb, Jonathan ^a   Smith, James ^a   Novembre, Francis ^b   Hazuda, Daria ^c   Gerardo Garcia Lerma, J ^a   Heneine, Walid ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE INHIBITOR; L 870812; PLACEBO; RALTEGRAVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SOLUBILITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LOW DRUG DOSE; NONHUMAN; PRIMATE DISEASE; PRIORITY JOURNAL; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEXUAL BEHAVIOR; VAGINA DISCHARGE; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; BODY FLUIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; FEMALE; GELS; INTEGRASE INHIBITORS; KINETICS; MACACA; POST-EXPOSURE PROPHYLAXIS; PROGESTERONE; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; VAGINA; VIRAL LOAD; VIRUS REPLICATION;

EID: 84897502032     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007701     Document Type: Article

References (38)

1. Q. Abdool Karim, S. S. Abdool Karim, J. A. Frohlich, A. C. Grobler, C. Baxter, L. E. Mansoor, A. B. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, D. Taylor; CAPRISA 004 Trial Group, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
2. The VOICE Study (MTN-003) (2013).
3. J. Marrazzo, G. Ramjee, G. Nair, T. Palanee, B. Mkhize, C. Nakabiito, M. Taljaard, J. Piper, K. Gomez, M. Chirenje, Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003), paper presented at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3 to 6 March 2013.
4. L. Van Damme, A. Corneli, K. Ahmed, K. Agot, J. Lombaard, S. Kapiga, M. Malahleha, F. Owino, R. Manongi, J. Onyango, L. Temu, M. C. Monedi, P. Mak'Oketch, M. Makanda, I. Reblin, S. E. Makatu, L. Saylor, H. Kiernan, S. Kirkendale, C. Wong, R. Grant, A. Kashuba, K. Nanda, J. Mandala, K. Fransen, J. Deese, T. Crucitti, T. D. Mastro, D. Taylor; FEM-PrEP Study Group, Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411-422 (2012).
5. C. S. Dezzutti, C. Shetler, A. Mahalingam, S. R. Ugaonkar, G. Gwozdz, K. W. Buckheit, R. W. Buckheit Jr., Safety and efficacy of tenofovir/IQP-0528 combination gels-A dual compartment microbicide for HIV-1 prevention. Antiviral Res. 96, 221-225 (2012).
6. U. M. Parikh, C. Dobard, S. Sharma, M. E. Cong, H. Jia, A. Martin, C. P. Pau, D. L. Hanson, P. Guenthner, J. Smith, E. Kersh, J. G. Garcia-Lerma, F. J. Novembre, R. Otten, T. Folks, W. Heneine, Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 83, 10358-10365 (2009).
7. R. S. Veazey, T. J. Ketas, J. Dufour, T. Moroney-Rasmussen, L. C. Green, P. J. Klasse, J. P. Moore, Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis. 202, 739-744 (2010).
8. J. Kenney, R. Singer, N. Derby, M. Aravantinou, C. J. Abraham, R. Menon, S. Seidor, S. Zhang, A. Gettie, J. Blanchard, M. Piatak Jr., J. D. Lifson, J. A. Fernández-Romero, T. M. Zydowsky, M. Robbiani, A single dose of a MIV-150/zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. AIDS Res. Hum. Retroviruses 28, 1476-1484 (2012).
9. M. Cranage, S. Sharpe, C. Herrera, A. Cope, M. Dennis, N. Berry, C. Ham, J. Heeney, N. Rezk, A. Kashuba, P. Anton, I. McGowan, R. Shattock, Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLOS Med. 5, e157 (2008).
10. C. Dobard, S. Sharma, A. Martin, C. P. Pau, A. Holder, Z. Kuklenyik, J. Lipscomb, D. L. Hanson, J. Smith, F. J. Novembre, J. G. García-Lerma, W. Heneine, Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J. Virol. 86, 718-725 (2012).
11. E. Asante-Appiah, A. M. Skalka, HIV-1 integrase: Structural organization, conformational changes, and catalysis. Adv. Virus Res. 52, 351-369 (1999).
12. D. Esposito, R. Craigie, HIV integrase structure and function. Adv. Virus Res. 52, 319-333 (1999).
13. E. Tramontano, L. Onidi, F. Esposito, R. Badas, P. La Colla, The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3'-ends increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors. Biochem. Pharmacol. 67, 1751-1761 (2004).
14. A. Pendri, N. A. Meanwell, K. M. Peese, M. A. Walker, New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Expert Opin. Ther. Pat. 21, 1173-1189 (2011).
15. Z. Hayouka, A. Levin, M. Maes, E. Hadas, D. E. Shalev, D. J. Volsky, A. Loyter, A. Friedler, Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370. Biochem. Biophys. Res. Commun. 394, 260-265 (2010).
16. D. J. Hazuda, S. D. Young, J. P. Guare, N. J. Anthony, R. P. Gomez, J. S. Wai, J. P. Vacca, L. Handt, S. L. Motzel, H. J. Klein, G. Dornadula, R. M. Danovich, M. V. Witmer, K. A. Wilson, L. Tussey, W. A. Schleif, L. S. Gabryelski, L. Jin, M. D. Miller, D. R. Casimiro, E. A. Emini, J. W. Shiver, Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305, 528-532 (2004).
17. M. D. Marsden, P. A. Krogstad, J. A. Zack, Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens. Antivir. Ther. 17, 1375-1379 (2012).
18. J. A. Grobler, K. Stillmock, B. Hu, M. Witmer, P. Felock, A. S. Espeseth, A. Wolfe, M. Egbertson, M. Bourgeois, J. Melamed, J. S. Wai, S. Young, J. Vacca, D. J. Hazuda, Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U. S. A. 99, 6661-6666 (2002).
19. K. E. Hightower, R. Wang, F. Deanda, B. A. Johns, K. Weaver, Y. Shen, G. H. Tomberlin, H. L. Carter III, T. Broderick, S. Sigethy, T. Seki, M. Kobayashi, M. R. Underwood, Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55, 4552-4559 (2011).
20. D. A. Donahue, R. D. Sloan, B. D. Kuhl, T. Bar-Magen, S. M. Schader, M. A. Wainberg, Stagedependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob. Agents Chemother. 54, 1047-1054 (2010).
21. L. Livingston, E. Sweeney, J. Mitchell, W. Luo, K. Paul, N. Powell, R. Michael Hendry, J. McNicholl, E. Kersh, Hormonal synchronization of the menstrual cycles of pigtail macaques to facilitate biomedical research including modeling HIV susceptibility. J. Med. Primatol. 40, 164-170 (2011).
22. C. D. Pilcher, H. C. Tien, J. J. Eron Jr., P. L. Vernazza, S. Y. Leu, P. W. Stewart, L. E. Goh, M. S. Cohen; Quest Study; Duke-UNC-Emory Acute HIV Consortium, Brief but efficient: Acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189, 1785-1792 (2004).
23. S. A. Vishwanathan, P. C. Guenthner, C. Y. Lin, C. Dobard, S. Sharma, D. R. Adams, R. A. Otten, W. Heneine, R. M. Hendry, J. M. McNicholl, E. N. Kersh, High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J. Acquir. Immune Defic. Syndr. 57, 261-264 (2011).
24. B. Poonia, L. Walter, J. Dufour, R. Harrison, P. A. Marx, R. S. Veazey, Cyclic changes in the vaginal epithelium of normal rhesus macaques. J. Endocrinol. 190, 829-835 (2006).
25. C. Dobard, S. Sharma, Impact of Depo-Provera and menstrual cycle on vaginal absorption of antiretroviral drugs from gels in pigtail macaques, paper presented at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3 to 6 March 2013.
26. J. Atashili, C. Poole, P. M. Ndumbe, A. A. Adimora, J. S. Smith, Bacterial vaginosis and HIV acquisition: A meta-analysis of published studies. AIDS 22, 1493-1501 (2008).
27. A. M. Weiler, Q. Li, L. Duan, M. Kaizu, K. L. Weisgrau, T. C. Friedrich, M. R. Reynolds, A. T. Haase, E. G. Rakasz, Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. J. Virol. 82, 4154-4158 (2008).
28. F. Christ, Z. Debyser, The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology 435, 102-109 (2013).
29. H. H. Sigurdsson, J. Kirch, C. M. Lehr, Mucus as a barrier to lipophilic drugs. Int. J. Pharm. 453, 56-64 (2013).
30. J. M. Smith, R. Rastogi, R. S. Teller, P. Srinivasan, P. M. Mesquita, U. Nagaraja, J. M. McNicholl, R. M. Hendry, C. T. Dinh, A. Martin, B. C. Herold, P. F. Kiser, Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc. Natl. Acad. Sci. U. S. A. 110, 16145-16150 (2013).
31. J. Münch, U. Sauermann, M. Yolamanova, K. Raue, C. Stahl-Hennig, F. Kirchhoff, Effect of semen and seminal amyloid on vaginal transmission of simian immunodeficiency virus. Retrovirology 10, 148 (2013).
32. S. L. Karmon, M. Markowitz, Next-generation integrase inhibitors: Where to after raltegravir? Drugs 73, 213-228 (2013).
33. M. Tsiang, G. S. Jones, A. Niedziela-Majka, E. Kan, E. B. Lansdon, W. Huang, M. Hung, D. Samuel, N. Novikov, Y. Xu, M. Mitchell, H. Guo, K. Babaoglu, X. Liu, R. Geleziunas, R. Sakowicz, New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J. Biol. Chem. 287, 21189-21203 (2012).
34. R. A. Otten, D. R. Adams, C. N. Kim, E. Jackson, J. K. Pullium, K. Lee, L. A. Grohskopf, M. Monsour, S. Butera, T. M. Folks, Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: Strategy to study HIV preclinical interventions in nonhuman primates. J. Infect. Dis. 191, 164-173 (2005).
35. S. Subbarao, R. A. Otten, A. Ramos, C. Kim, E. Jackson, M. Monsour, D. R. Adams, S. Bashirian, J. Johnson, V. Soriano, A. Rendon, M. G. Hudgens, S. Butera, R. Janssen, L. Paxton, A. E. Greenberg, T. M. Folks, Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J. Infect. Dis. 194, 904-911 (2006).
36. J. G. García-Lerma, R. A. Otten, S. H. Qari, E. Jackson, M. E. Cong, S. Masciotra, W. Luo, C. Kim, D. R. Adams, M. Monsour, J. Lipscomb, J. A. Johnson, D. Delinsky, R. F. Schinazi, R. Janssen, T. M. Folks, W. Heneine, Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLOS Med. 5, e28 (2008).
37. W. Saltzman, N. J. Schultz-Darken, G. Scheffler, F. H. Wegner, D. H. Abbott, Social and reproductive influences on plasma cortisol in female marmoset monkeys. Physiol. Behav. 56, 801-810 (1994).
38. I. M. Longini Jr., S. Datta, M. E. Halloran, Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13, 440-447 (1996).